No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects

Diabetes, Obesity & Metabolism
Ronald A SmuldersTakeshi Kadokura

Abstract

To investigate the effect of ipragliflozin on the pharmacokinetics of sitagliptin, pioglitazone or glimepiride and vice versa in healthy subjects. Three trials with an open-label, randomized, two-way crossover design were conducted in healthy subjects. Ipragliflozin 150 mg, sitagliptin 100 mg, pioglitazone 30 mg or glimepiride 1-2 mg were administered alone or in combination. Primary endpoints were the area under the curve from the time of dosing to infinity (AUC(inf)) and the maximum observed plasma concentration (C(max)) of each drug. Multiple doses of ipragliflozin did not change the AUC(inf) and C(max) of a single dose of sitagliptin, pioglitazone or glimepiride. All geometric mean ratios and 90% CIs for AUC(inf) and C(max) , with and without ipragliflozin, were within the predefined range of 80-125% (AUC(inf) : sitagliptin 100.1 [96.9-103.5], pioglitazone 101.7 [96.6-107.0], glimepiride 105.1 [101.3-109.0], and C(max) : sitagliptin 92.4 [82.8-103.1], pioglitazone 98.6 [87.7-110.8], glimepiride 110.0 [101.9-118.8]). Similarly, multiple doses of sitagliptin, pioglitazone or glimepiride did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; a...Continue Reading

References

Oct 1, 1994·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·C R Sirtori, C Pasik
Jan 3, 2001·American Journal of Physiology. Renal Physiology·E M Wright
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Sharon H SaydahCatherine C Cowie
Mar 28, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Olivera Marsenic
Sep 15, 2009·Best Practice & Research. Clinical Endocrinology & Metabolism·Nancy A Thornberry, Baptist Gallwitz
Jul 2, 2010·Diabetes, Obesity & Metabolism·A J Scheen

❮ Previous
Next ❯

Citations

Apr 17, 2014·Diabetes Research and Clinical Practice·Farhad M HasanJohn E Gerich
Mar 29, 2014·Drugs·Raewyn M Poole, Rosselle T Dungo
May 16, 2014·Cardiovascular Drugs and Therapy·L H Opie
Oct 16, 2014·Clinical Pharmacokinetics·Takeshi KadokuraRonald Smulders
Feb 3, 2015·Expert Opinion on Drug Metabolism & Toxicology·Maka S Hedrington, Stephen N Davis
Apr 22, 2014·Expert Opinion on Drug Metabolism & Toxicology·Theodosios D FilippatosMoses S Elisaf
Oct 20, 2012·Annales d'endocrinologie·Thomas CunyBertrand Cariou
Oct 15, 2014·Clinical and Experimental Pharmacology & Physiology·Toshiyuki TakasuShoji Takakura
Mar 14, 2014·The Lancet. Diabetes & Endocrinology·Abd A TahraniClifford J Bailey
Jul 28, 2016·Expert Opinion on Investigational Drugs·K PafiliN Papanas
Jul 31, 2019·Phytotherapy Research : PTR·Reyhaneh Moradi-MarjanehAmirhossein Sahebkar
Apr 11, 2020·Translational and Clinical Pharmacology·Namyi GuTae-Eun Kim
Jun 19, 2018·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·Ahmed ElgebalyNoha Nasreldin
Nov 28, 2017·Drug Metabolism and Pharmacokinetics·Kenta HarayaYuichi Sugiyama

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.